Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business equity offering

Innocan Pharma Private Placement of Units

Analysis based on 14 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026

Sentiment
5
Attention
1
Articles
14
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The private placement is a modest capital raise for Innocan Pharma, providing up to C$1 million in working capital. The offering may slightly dilute existing shareholders but signals continued operational funding, with a neutral to slightly positive impact on the company's liquidity.

Pharmaceuticals Wellness

Innocan Pharma Corporation announced on September 9, 2026 its intention to complete a private placement of up to 535,000 units at C$1.87 per unit, for gross proceeds of up to C$1,000,000. Each unit consists of one common share and one common share purchase warrant, with each warrant exercisable at C$2.50 for three years. The offering is expected to close on or around September 17, 2026. Proceeds will be used for working capital and general corporate purposes. The company will pay a finder's fee of 10% in cash and 8% finder's warrants to arm's length finders. Securities issued will be subject to a four-month-and-one-day hold period. The offering is not registered in the United States.

80 Innocan Pharma Corporation announced private placement
stock
Innocan Pharma is the issuer of the private placement, raising up to C$1 million to fund working capital and general corporate purposes. The offering provides additional capital but may dilute existing shareholders.
Importance 100.0 Sentiment 0.0
exch
The Canadian Securities Exchange is the listing exchange for Innocan's common shares and will oversee the trading of the newly issued securities, subject to its policies and hold period requirements.
Importance 20.0 Sentiment 0.0
per
Iris Bincovich is the CEO of Innocan Pharma and is listed as a contact for the offering, representing the company in the private placement.
Importance 10.0 Sentiment 0.0
priv
B.I. Sky Global Ltd. is a 60%-owned subsidiary of Innocan Pharma focused on online sales of wellness products. The offering's proceeds may indirectly support its operations, but it is not directly involved in the placement.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.